# A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer

> **NCT02133742** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 52 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** Axitinib
- **DRUG:** MK-3475

## Key facts

- **NCT ID:** NCT02133742
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-16
- **Primary completion:** 2017-03-31
- **Final completion:** 2019-07-03
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2021-07-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02133742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02133742, "A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02133742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*